Drugs and FDA

Survodutide cut weight by up to 9.8% in adults with diabetes and obesity

In the 76-week trial, gastrointestinal side effects led 18% of participants in each survodutide dose group to stop treatment.

Reported by 4 outlets Friday, October 2, 2026

A blood glucose meter showing a reading
Photo: CC0

Survodutide reduced body weight in adults with type 2 diabetes and overweight or obesity in the phase 3 SYNCHRONIZE-2 trial, according to findings presented at a European diabetes meeting and published in The New England Journal of Medicine. In the treatment-regimen analysis, participants lost an average of 8.2% of their weight on 3.6 mg and 9.8% on 6 mg at 76 weeks, compared with 3.9% with placebo. Healio reported a separate analysis estimating weight loss of 10.4% and 13.1% with the two doses, compared with 3.1% with placebo.

Gastrointestinal adverse events were reported by 72.8% of the 3.6 mg group and 77.7% of the 6 mg group, compared with 38.6% of the placebo group. These events led 18% and 17.9% of participants in the survodutide groups to stop treatment, compared with 1.2% in the placebo group. Boehringer Ingelheim said future trials will use more flexible, patient-centered dose increases to improve tolerability.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.